Aadi Bioscience Inc

Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing highly targeted therapies for cancers defined by specific genetic alterations within the mTOR pathway. Its flagship drug candidate, FYARRO, is an investigational therapeutic composed of sirolimus conjugated with albumin. Aadi is actively evaluating FYARRO's efficacy in various malignancies that exhibit known mTOR pathway activation. This includes its application in 'tumor-agnostic' indications, where the focus is on specific genomic alterations that activate the mTOR pathway, irrespective of the tumor's origin. The company was established in 2007 and maintains its corporate headquarters in Pacific Palisades, California.